ALKERMES, INC.

Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 2163/S. 464 the Safe Step Act; Policies impacting pharmaceutical development, reimbursement, and patient access and cost; Awareness of need for transparency and patient access within the 340B program; H.R. 2882 Further Consolidated Appropriations Act, 2024; Labor, Health and Human Services, Education Appropriations, 2025; Commerce, Justice, Science, and Related Agencies Appropriations, 2025; Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, 2025; Support FDA efficiency reforms

Expand funding and flexibility to address all substance use disorders;

Patient access and maintain six protected class status of medicines to treat serious mental illness under Medicare Part D; Inflation Reduction Act of 2022 implementation; Medicaid Drug Rebate Program proposed rule Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program